Previously presented at the 8th Annual Meeting of the Society for Melanoma Research; November 9-13, 2011; Tampa, FL.
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma
Article first published online: 26 MAR 2014
© 2014 American Cancer Society
Volume 120, Issue 13, pages 2016–2024, 1 July 2014
How to Cite
Hamid, O., Ilaria, R., Garbe, C., Wolter, P., Maio, M., Hutson, T. E., Arance, A., Lorigan, P., Lee, J., Hauschild, A., Mohr, P., Hahka-Kemppinen, M., Kaiser, C., Turner, P. K., Conti, I. and Grob, J.-J. (2014), A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Cancer, 120: 2016–2024. doi: 10.1002/cncr.28635
We thank Cindy C. Taylor PhD of Medical Communication Consultants for assisting with article preparation, Lisa Cirri and Scott Saxman for medical/clinical trial oversight, and Dinesh P. DeAlwis and Kay Chow for their work on the pharmacokinetic analyses. We are grateful to all who participated in this trial.
- Issue published online: 17 JUN 2014
- Article first published online: 26 MAR 2014
- Manuscript Accepted: 9 DEC 2013
- Manuscript Revised: 3 DEC 2013
- Manuscript Received: 23 AUG 2013